assays could lead to an inappropriate discharge, while more sensitive troponin assays may result in avoidable diagnostic testing. Published data about the impact of the use of more sensitive cTn assays compared with the conventional ones on the actual managements and outcomes of chest pain patients presenting to the ED are inconclusive. 6, [11] [12] [13] More researches are needed to test whether the clinical consequences are altered when the more sensitive cTn assays are used in different health settings.
The introduction of a more sensitive cTnI assay in our laboratory allowed us a unique opportunity to assess the clinical implications of two different cTnI assays. In this study, we decided to investigate whether the alteration of cTn assays was associated with changes in (a) length of stay (LOS) in the ED; (b) hospital admission rate; (c) the use of diagnostic measures and cardiovascular therapies; and (d) the incidence of major adverse cardiac events (MACE) at 30 days.
| METHODS

| Study population
This is a pre-post cohort study. We performed a retrospective analysis of data which were collected prospectively. We identified all consecutive patients aged ≥18 years presenting to the ED with acute nontraumatic chest pain or equivalent ischemic symptoms suggestive of ACS with an onset or peak within the last 24 hours in Qilu Hospital of Shandong University, a tertiary and teaching hospital with about 110 000 ED visits per year. Equivalent ischemic symptoms suggestive of ACS included shortness of breath, nausea, vomiting, jaw pain, arm pain, etc.
14 On May 10, 2016, a new Access AccuTnI+3 (Beckman Coulter, Inc. Brea, California) was introduced into our laboratory. Previously, the AccuTnI (Beckman Coulter, Inc. Fullerton, California), a conventional cTnI assay had been used for more than 10 years.
The study cohort was allocated to two groups according to the cTn assay used: (a) study period 1 (from September 1, 2015 to May 9, 2016), using the conventional cTnI assay; (b) study period 2 (from September 1, 2016 to May 9, 2017), using the more sensitive cTnI assay. Patients presenting in the time interval between the two periods were not considered, to alleviate the effects of seasonal variation.
Patients were excluded from analysis if (a) a point-of-care assay to test cTnI levels was used, (b) they were transferred from another hospital, (c) there was a new ST-segment elevation or left bundle branch block in the initial electrocardiogram (ECG) suggesting ST-segment elevation MI, (d) no cTnI level was measured, and (e) they were unwilling to provide informed consent.
The study was approved by the ethics committee of the hospital, and all patients included provided written informed consent.
| Troponin assays
Patients in the study period 1 underwent cTnI testing by Access AccuTnI, which had a 99th percentile upper reference limit (URL) of 0.04 ng/mL with a median imprecision of 14% coefficient of variation (CV), and a 10% CV at 0.06 ng/mL. 15 Our central laboratory used 0.06 ng/mL suggested by the manufacturer as the diagnostic threshold for this conventional cTnI assay.
Patients in the study period 2, underwent testing using Access AccuTnI+3. The 10% CV was at 40 ng/L. The 99th percentile URL was 30 ng/L, and this was used as the diagnostic threshold for this more sensitive cTnI assay.
| Patient management
All patients underwent an initial assessment, including clinical history, physical examination, ECG, and blood tests. Generally, patients who were considered to have a benign cause for their complaint were discharged directly from the ED, while those who had a life-threatening condition and needed urgent invasive management were admitted to hospital immediately. The remaining patients were scheduled for admission or observation. Blood samples were drawn based on physician judgment, but not at established time intervals.
There was no relevant change in patient flow, staff to patient ratio, cardiac catheterization laboratory availability, or funding practice during the enrollment period. Clinical management was at the discretion of the physician on duty. All patients who were diagnosed with AMI received antithrombotic treatment consisting of aspirin, a P2Y 12 inhibitor, and low molecular weight heparin (LMWH), unless there was any contraindication. Stress testing was seldom performed in our hospital. In general, coronary computed tomography angiography (CCTA) was used to rule out ACS. Most low-and intermediaterisk patients evaluated in the ED only received medical therapy.
Patients with recurrent angina despite intensive medical therapy or with positive cTn detection were scheduled to undergo coronary angiography (CAG) unless they refused.
| Data collection
Data were collected on standardized case report forms using clinical data standards by trained research staff. 14 Both ED and hospital datasets were fully accessed. An electronic data capture system was used to guarantee the integrity and authenticity of the data. Patients were followed up by trained researchers at 30 days through telephone. The local death registry data were checked when patients were lost to follow up to ensure that they were deceased or not. and UA were diagnosed according to the international recommendations, using the cTnI assay that was used for the patients in the clinical practice. 3, 14 In brief, AMI referred to type 1 MI and was diagnosed when there was evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia due to definite or highly suspected plaque rupture and coronary thrombosis. Myocardial necrosis was identified by a detection of a rise and/or fall of cTnI with at least one value above the diagnostic threshold. According to the guideline, a minimum of a 20% cTn concentration change was required. 16 UA was defined as angina occurring at rest and prolonged, or recent acceleration of angina increased from at least 1 Canadian Cardiovascular Society (CCS) class to at least CCS class III; it also included new-onset angina of at least CCS class III, with coronary artery stenosis ≥70%, and without evidence of necrosis. Other cardiac diseases included type 2 MI (myocardial necrosis caused by arrhythmia, hypertensive urgency, coronary artery spasm, and the like), 3 acute heart failure, myocarditis, pericarditis, and stable angina, among others.
| Statistical analysis
Continuous variables were presented as means ± SDs or medians (with 25th and 75th percentiles), and ANOVA and Kruskal-Wallis test were used to compare the differences when appropriate. Categorical variables were expressed as numbers and percentages. When comparing the differences, x 2 or Fisher's exact test were used.
Multivariable stepwise logistic regression analysis was used to investigate the association between the type of cTnI assay and the length of ED stay, hospital admission rate, the use of echocardiography, CCTA, CAG, PCI, and the incidence of MACE. Age, sex, previous MI, heart failure, hypertension, previous stroke, tobacco smoking, diabetes mellitus, family history, and ischemic ECG were included in the models.
All hypothesis testing was two-tailed, and P values of less than 0.05 were considered to indicate statistical significance. Data were analyzed using SAS 9.4.
3 | RESULTS
| Clinical characteristics
A total of 1201 patients were identified for this study (study period 1, 633 visits; study period 2, 568 visits). Among them, 399 (63.03%) patients were discharged home in period 1 vs 311 (54.75%) patients in period 2 ( Figure 1 ). The baseline characteristics of patients in these two groups were similar. Use of the more sensitive cTnI assay F I G U R E 1 Flow diagram of patients in the study increased the proportion of patients with positive cTnI of the first measurement (10.90% vs 19.37%, P < 0.01), and decreased the proportion of patients with serial cTnI in the ED (15.01% vs 10.74%, P = 0.03), see Table 1 .
| Final clinical diagnoses
Compared with period 1, more patients were considered to have AMI in period 2 (9.79% vs 16.02%, P < 0.01), while the proportion of patients with UA did not decrease significantly (23.38% vs 22.89%, P = 0.84) ( Table 2 ).
3 2.32 hours, P < 0.01). The proportion of hospitalized patients increased when the more sensitive assay was used (35.23% vs 43.04%, P = 0.01) ( Table 3) .
Information for procedures are also provided in Table 3 . More patients in period 2 received echocardiography (23.38% vs 32.42%, P < 0.01), CCTA (3.73% vs 6.41%, P = 0.04), CAG (12.66% vs 18.50%, P = 0.01), and PCI (6.75% vs 15.23%, P < 0.01).
In the follow-up period, a total of 4 (0.63%) patients were lost in period 1, and 1 (0.18%) was lost in period 2. The incidences of MACE (2.78% vs 1.65%, P = 0.20) were not significantly different.
The readmission rate decreased (10.93% vs 7.01%, P = 0.02) in period 2 (Table 3) . Among patients directly discharged home in period 1, five patients suffered MACE, while no MACE occurred during period 2.
Following multivariable adjustment for potential confounders, the median LOS in the ED decreased in period 2 regarding patients discharged home (OR 0.39, 95% CI 0.28-0.54, P < 0.01). The hospital admission rate (OR 1.43, 95% CI 1.12-1.84, P < 0.01), the use of echocardiography (OR 1.58, 95% CI 1.22-2.06, P < 0.01), CCTA (OR 1.78, 95% CI 1.04-3.06, P = 0.04), CAG (OR 1.53, 95% CI 1.10-2.12, P = 0.01) or PCI (OR 2.42, 95% CI 1.58-3.70, P < 0.01) were increased, while the incidence of MACE did not change significantly (OR 0.61, 95% CI 0.27-1.37, P = 0.23) ( Table 4) . T A B L E 3 Medication in the first 24 hours in the ED, coronary status, and outcomes of patients discharged or hospitalized in the two groups
T A B L E 2 Final diagnoses during initial presentation
Period 2 (n = 546)
Pvalue
Medication in the first 24 hours in the ED, n (%) more sensitive assays in patients with acute chest pain presenting to the ED were inconclusive in previous studies. [11] [12] [13] Yip et al found the use of CAG was increased, while revascularization procedures did not alter statistically. 11 Sanchis et al showed that use of the highsensitivity assay increased the rates of CAG and revascularization, while led to a reduction of non-invasive tests. 12 However, no increase of invasive procedures was found in the APACE trial. 13 High-STEACS, a stepped-wedge, clusterrandomized controlled trial also showed that the use of a highsensitivity cTn was not associated with a lower incidence of MACE. 6 Troponin cannot be a substitute for careful clinical assessment, and it must be interpreted in the context of the history of each patient. More researches are necessary to determine the preferred clinical protocols to integrate the high-sensitivity assays into the clinical practice.
Our study had several limitations. First, it was a single center observational study and the sample scale was small. Different healthcare models and potential confounding factors that were unmeasured may influence the results. The study needs to be repeated on larger scales and with multi-center trials. Second, we evaluated two cTnI assays, which had different analytical performances and were released by the same supplier. The results may not be generalized to other cTn assays. Finally, we did not collect data on coronary artery bypass grafting and discharge medication, and the follow-up period in our study was short. The long-term outcomes should be further researched.
| CONCLUSIONS
The implementation of the more sensitive cTn assay was likely to identify patients for safe discharge much earlier, although prompted more hospital admissions and procedures without impacting on the incidence of MACE at 30 days. 
